Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Edward Lee Carter: 61% of Patients on Reduced-Dose Apixaban Did Not Meet Label Criteria
Edward Lee Carter/LinkedIn
Aug 10, 2026, 15:47

Edward Lee Carter: 61% of Patients on Reduced-Dose Apixaban Did Not Meet Label Criteria

Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared a post on LinkedIn about a recent article by Pishoy Gouda etv al., published in JACC: Advances, adding:

“Apixaban 2.5 mg BID isn’t simply the ‘safer dose.’

It’s the correct dose for a specific patient population.

A new JACC: Advances analysis of real-world apixaban prescribing caught my attention:

61% of patients receiving reduced-dose apixaban did not meet the labeled criteria for dose reduction.

For stroke prevention in nonvalvular atrial fibrillation, the rule is worth remembering:

Think 2 of 3

  • Age 80 years or older
  • Weight 60 kg or less
  • Serum creatinine 1.5 mg/dL or higher

Meet at least 2 of 3, use apixaban 2.5 mg BID

Meet 0 or 1, use generally 5 mg BID, per labeling.

Why does inappropriate dose reduction happen?

The reasoning is often understandable:

  • ‘They’re elderly.’
  • ‘They’re frail.’
  • ‘Their kidneys aren’t great.’
  • ‘I’m worried about bleeding.’

Those factors absolutely deserve clinical consideration.

But they don’t independently rewrite the dose-reduction criteria.

And importantly, this study did not show that inappropriate dose reduction provided a major-bleeding advantage.

It also did not prove that every off-label dose reduction causes stroke – this was observational evidence, and that distinction matters.

What it does reveal is a persistent medication-safety opportunity.

This is anticoagulation stewardship at its most practical:

  • Verify the indication.
  • Verify the dose.
  • Check current weight and renal function.
  • Reassess as patients age and clinical circumstances change.

And perhaps most importantly:

Don’t confuse dose reduction with risk reduction.

Sometimes the safest anticoagulant dose isn’t the lower dose.

It’s the correct dose.

Important: these criteria apply to NVAF dosing. Apixaban 2.5 mg BID has other evidence-based indications, including extended VTE therapy.”

Title: Clinical Patterns and Appropriateness of Apixaban Dosing in Patients With Atrial Fibrillation

Authors: Pishoy Gouda, Josephine Harrington, Kelly Arps, Gretchen Sanders, Anqi Chen, Karen Chiswell, Paul Hofmann, Keith Marsolo, Kirubel Asfaw, Rosa Coppolecchia, John H. Alexander, Jonathan Piccini, Christopher B. Granger, Heidi T. May, Elizabeth Chrischilles, Benjamin A. Steinberg, Alanna M. Chamberlain, Jeffrey VanWormer, W. Schuyler Jones, Manesh R. Patel

Edward Lee Carter

Other posts featuring Edward Lee Carter on Hemostasis Today.

AF Alanna M. Chamberlain Anqi Chen Anticoagulation Apixaban Benjamin A. Steinberg bleeding disorders Blood Christopher B. Granger DOACs Edward Lee Carter Elizabeth Chrischilles Gretchen Sanders Health Heidi T. May Hematology Hemostasis Hemostasis News Hemostasis Today JACC: Advances Jeffrey VanWormer John H. Alexander Jonathan Piccini Josephine Harrington Karen Chiswell Keith Marsolo Kelly Arps Kirubel Asfaw Manesh   R. Patel Medicine nonvalvular atrial fibrillation NVAF Paul Hofmann Pishoy Gouda Rosa Coppolecchia VTE W. Schuyler Jones
NewsFeed